BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21187510)

  • 21. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
    J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer.
    Bosch-Barrera J; Gaztañaga M; Ceballos J; Pérez-Gracia JL; López-Picazo JM; García-Foncillas J; Ferrer M; Sanz ML; Pretel M; Idoate MA; Gil-Bazo I
    Onkologie; 2009 Oct; 32(10):580-4. PubMed ID: 19816075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option.
    Razak AR; Chatten KJ; Hughes AN
    Lung Cancer; 2008 May; 60(2):294-7. PubMed ID: 17919769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Seeking new options for the treatment of small-cell lung cancer.
    Socinski MA
    Lung Cancer; 2005 Oct; 50 Suppl 1():S25-6. PubMed ID: 16291430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pemetrexed in first-line treatment of non-small cell lung cancer.
    Esteban E; Casillas M; Cassinello A
    Cancer Treat Rev; 2009 Jun; 35(4):364-73. PubMed ID: 19269106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
    Scagliotti GV; Kortsik C; Dark GG; Price A; Manegold C; Rosell R; O'Brien M; Peterson PM; Castellano D; Selvaggi G; Novello S; Blatter J; Kayitalire L; Crino L; Paz-Ares L
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):690-6. PubMed ID: 15701857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
    Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS
    Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pemetrexed-induced lung toxicity: a case report.
    Breuer S; Nechushtan H
    Clin Oncol (R Coll Radiol); 2012 Feb; 24(1):76-7. PubMed ID: 21924594
    [No Abstract]   [Full Text] [Related]  

  • 29. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF; Chen ZW; Lu S
    Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer.
    Garin A; Manikhas A; Biakhov M; Chezhin M; Ivanchenko T; Krejcy K; Karaseva V; Tjulandin S
    Breast Cancer Res Treat; 2008 Jul; 110(2):309-15. PubMed ID: 17851759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pemetrexed-induced cellulitis: a rare toxicity in non-small cell lung cancer treatment.
    Katsenos S; Psara A; Panagou C
    J Oncol Pharm Pract; 2013 Mar; 19(1):93-4. PubMed ID: 22357637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pemetrexed and maintenance therapy for non-small cell lung cancer.
    Prescrire Int; 2011 Feb; 20(113):39. PubMed ID: 21488588
    [No Abstract]   [Full Text] [Related]  

  • 33. Anaphylactic reaction to pemetrexed: a case report.
    Capelle H; Birnbaum J; Tomasini P; Tummino C; Gouitaa M; Ausias N; Charpin D; Barlesi F; Montana M
    J Pharm Pharm Sci; 2014; 17(2):229-30. PubMed ID: 24934551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral skin edema as unusual toxicity in three patients with advanced non-small cell lung cancer treated with pemetrexed alone or in combination with cisplatin.
    Galetta D; Silvestris N; Catino A; Colucci G
    J Thorac Oncol; 2011 Nov; 6(11):1964. PubMed ID: 22005477
    [No Abstract]   [Full Text] [Related]  

  • 35. Pemetrexed-induced skin sclerosis.
    Merklen-Djafri C; Imbert E; Courouge-Dorcier D; Schott R; Méraud JP; Muller C; Tebacher M; Springinsfeld G; Cribier B; Lipsker D
    Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):452-3. PubMed ID: 22397832
    [No Abstract]   [Full Text] [Related]  

  • 36. [Role of pemetrexed given with radiotherapy].
    Mornex F
    Rev Pneumol Clin; 2005 Sep; 61(4 Pt 2):4S18-9. PubMed ID: 16273005
    [No Abstract]   [Full Text] [Related]  

  • 37. Subacute cutaneous lupus erythematosus associated with pemetrexed plus Carboplatin chemotherapy.
    González García A; Sifuentes Giraldo WA; Grillo Fernández E; Zea Mendoza A
    J Clin Rheumatol; 2014 Dec; 20(8):449-50. PubMed ID: 25417687
    [No Abstract]   [Full Text] [Related]  

  • 38. Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis.
    Barlési F; Tummino C; Tasei AM; Astoul P
    Lung Cancer; 2006 Dec; 54(3):423-5. PubMed ID: 17049669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interstitial pneumonitis after treatment with pemetrexed: a rare event?
    Hochstrasser A; Benz G; Joerger M; Templeton A; Brutsche M; Früh M
    Chemotherapy; 2012; 58(1):84-8. PubMed ID: 22377772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
    Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
    Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.